Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta).
In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 Increased by +100.00% | -1.08 Increased by +100.00% |
| Nov 10, 23 | 0.00 Decreased by N/A% | 0.04 Decreased by -100.00% |
| Jul 31, 23 | 0.97 Increased by +201.04% | -0.06 Increased by +1.86 K% |
| May 31, 23 | 0.00 Increased by +100.00% | -0.06 Increased by +100.00% |
| Feb 27, 23 | -1.02 Decreased by -251.72% | -1.02 |
| Nov 11, 22 | 0.00 Decreased by N/A% | -0.70 Increased by +100.00% |
| Aug 1, 22 | -0.96 Decreased by -190.91% | -0.72 Decreased by -33.33% |
| Jun 1, 22 | -0.70 Decreased by -102.25% | -0.70 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 22 | 208.44 M Increased by +50.87% | -184.44 M Decreased by -592.72% | Decreased by -88.49% Decreased by -359.16% |
| Sep 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Mar 31, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Dec 31, 21 | 138.16 M Increased by +127.97% | -26.63 M Increased by +29.96% | Decreased by -19.27% Increased by +69.28% |
| Sep 30, 21 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 21 | 75.81 M Increased by +37.34% | -77.46 M Decreased by -130.86% | Decreased by -102.18% Decreased by -68.09% |
| Mar 31, 21 | 75.81 M Increased by +47.00% | -77.46 M Decreased by -379.90% | Decreased by -102.18% Decreased by -226.47% |